skip to content

Cancer Research UK Cambridge Institute

Senior Research Associate

Research Group Home Page: 


Current

I’m a molecular biologist focus on translational research in high grade serous ovarian cancer (HGSOC). I work on identification of genomic biomarkers that could be applied in clinic as diagnostic, prognostic and predictive biomarkers, helping in better patient stratification, earlier disease diagnosis, monitoring patient response and improving patient management during the course of treatment. My research interests focus on development and implementation of new genomic technologies with potential application in clinic like shallow whole genome sequencing for copy number alterations detection and detection of mutant tumour DNA in body fluids.  In my research I use variety of specimens like tumour tissue and body fluids (blood, plasma, ascites). I have a special interest in molecular characterization of ascites samples. I’m engaged in molecular analysis of samples from several clinical trials (ARIEL2, PISSARO, ICON7, ICON8, MADCaP, PHL-093 Toronto, OZM-061 Toronto) and collaborate with scientists from other research centres: University of Calgary (Canada),  NKI (The Netherlands), VU University Medical Centre (The Netherlands), Institute of Cancer Sciences University of Glasgow (UK). I'm lead consultant for the molecular analysis of HGSOC samples in collaborations with the Ovarian Tumour Tissue Analysis (OTTA) and the Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG) consortiums. One of my main aims is to transform HGSOC patients' care in Addenbrooks's hospital through the implementation of real time molecular profiling of every women with HGSOC by setting up workflow between CRUK CI, pathologists, tissue bank and Cancer Molecular Diagnostic Laboratory.  

In addition to research I like sharing cancer research knowledge with the public, I participate in Cambridge Science Festival every year.

If I’m not in the lab I enjoy riding a motorbike, mountain hiking/climbing, horse-riding, swimming and practicing yoga.   


Previous

2017 - current Senior Research Associate, Brenton group, CRUK Cambridge Institute, University of Cambridge, UK

2010-2017 Research Associate, Brenton group, CRUK Cambridge Institute, University of Cambridge, UK

2005-2010 PhD in Medical Science (specialty: Basic Science), Department of Biology and Genetics, Medical University of Gdansk, Poland

2000-2010 MSc in Molecular Biology, Department of Biology and Genetics, University of Gdansk, Poland


Articles

Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.

Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HM, Qian W, Rosenfeld N, Brenton JD.

PLoS Med. 2016 Dec 20;13(12):e1002198. doi: 10.1371/journal.pmed.1002198. eCollection 2016 Dec.


Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD.

J Pathol Clin Res. 2016 Jul 13;2(4):247-258. eCollection 2016 Oct.


Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples.

Piskorz AM, Ennis D, Macintyre G, Goranova TE, Eldridge M, Segui-Gracia N, Valganon M, Hoyle A, Orange C, Moore L, Jimenez-Linan M, Millan D, McNeish IA, Brenton JD.

Ann Oncol. 2016 Mar;27(3):532-9. doi: 10.1093/annonc/mdv613. Epub 2015 Dec 17.

  

Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience.

Lee S, Piskorz AM, Le Page C, Mes Masson AM, Provencher D, Huntsman D, Chen W, Swanson PE, Gilks CB, Köbel M.

Int J Gynecol Pathol. 2016 May;35(3):209-21. doi: 10.1097/PGP.0000000000000251.

  

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.

Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ, Rosenfeld N, Earl HM, Sala E, Jimenez-Linan M, Parkinson CA, Markowetz F, Brenton JD.

PLoS Med. 2015 Feb 24;12(2):e1001789. doi: 10.1371/journal.pmed.1001789. eCollection 2015 Feb.

 

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J.

PLoS One. 2014 Sep 17;9(9):e103988. doi: 10.1371/journal.pone.0103988. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122284.


Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N.

Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.

  

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J, May AP, Caldas C, Brenton JD, Rosenfeld N.

Sci Transl Med. 2012 May 30;4(136):136ra68. doi: 10.1126/scitranslmed.3003726.

  

Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.

Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E, Biernat W, Debiec-Rychter M, Limon J.

Exp Hematol. 2011 Aug;39(8):859-65.e2. doi: 10.1016/j.exphem.2011.05.009. Epub 2011 May 27.

  

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.

Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry.

  

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

Mital A, Piskorz A, Lewandowski K, Wasąg B, Limon J, Hellmann A.

Eur J Haematol. 2011 Jun;86(6):531-5. doi: 10.1111/j.1600-0609.2011.01598.x. Epub 2011 Apr 7.

 

Cancer predisposing BARD1 mutations in breast-ovarian cancer families.

Ratajska M, Antoszewska E, Piskorz A, Brozek I, Borg Å, Kusmierek H, Biernat W, Limon J.

Breast Cancer Res Treat. 2012 Jan;131(1):89-97. doi: 10.1007/s10549-011-1403-8. Epub 2011 Feb 23.

 

Work address: 

Cancer Research UK Cambridge Institute
University of Cambridge
Li Ka Shing Centre
Robinson Way
Cambridge CB2 0RE

Recent publications: 

CRUKCI staff links